Oncotarget: Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

(Impact Journals LLC) Support recently reported findings of clinical benefit when relacorilant is added to paclitaxel-containing therapy in patients with ovarian and pancreatic cancers and provide a new rationale for combining relacorilant with additional cytotoxic agents.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

This article reviews the abnormal expression of miR-802 in a variety of tumors, expounds the mechanism by which miR-802 affects tumor progression by regulating different target genes, and elaborates the network of miR-802-related ceRNAs. We also summarized the limitations of miR-802 research and looked forward to the potential application of miR-802 in the diagnosis and prognosis of tumors.PMID:34558723 | DOI:10.1002/jcla.23989
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Eur J Pharmacol. 2021 Sep 18:174516. doi: 10.1016/j.ejphar.2021.174516. Online ahead of print.ABSTRACTNECTIN-4 [a poliovirus receptor-related-4 (pvrl-4) encoded protein] is a Ca2+ independent immunoglobulin-like protein. Along with other Nectins (Nectin-1, -2 and -3), it is primarily involved in cell-cell adhesion. In contrast to other Nectins, Nectin-4 is specifically enriched in the embryonic and placental tissues but its expression significantly declines in adult life. In recent years, it has been found that Nectin-4 is especially overexpressed and served as a tumor associated inducer in various malignant tumors includi...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
h Aurora-A kinase, a key mitosis regulator, is expressed in a cell cycle-dependent manner and has an essential role in maintaining chromosomal stability and the normal progression of the cell through mitosis. Aurora-A kinase is overexpressed in many malignant solid tumors, such as breast, ovarian, colon, and pancreatic cancers. Thus, inhibiting Aurora-A kinase activity is a promising approach for cancer treatment. Here, new triazole derivatives were designed as bioisosteric analogues of the known inhibitor JNJ-7706621. The new compounds showed interesting inhibitory activity against Aurora-A kinase, as attested by IC50...
Source: Molecules - Category: Chemistry Authors: Tags: Communication Source Type: research
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Swiss Med Wkly. 2021 Sep 13;151:w30038. doi: 10.4414/SMW.2021.w30038. eCollection 2021 Sep 13.ABSTRACTThis paper presents the Swiss guideline for genetic counselling and testing of individuals with an increased probability for carrying mutations in high risk cancer predisposition genes, particularly BRCA1 and BRCA2. It aims to help providers of genetic counselling to identify valuable candidates for testing and serves as a basis for reimbursement claims to Swiss insurance companies.PMID:34519462 | DOI:10.4414/SMW.2021.w30038
Source: Swiss Medical Weekly - Category: General Medicine Authors: Source Type: research
anlin Huang Germline BRCA1/2 mutations associated with HRD are clinical biomarkers for sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) treatment in breast, ovarian, pancreatic, and prostate cancers. However, it remains unclear whether other mutations may also lead to HRD and PARPi sensitivity across a broader range of cancer types. Our goal was to determine the germline or somatic alterations associated with the HRD phenotype that might therefore confer PARPi sensitivity. Using germline and somatic genomic data from over 9000 tumors representing 32 cancer types, we examined associations between HRD scores ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Collaboration Sought NCI Source Type: research
J Thromb Haemost. 2021 Sep 7. doi: 10.1111/jth.15519. Online ahead of print.ABSTRACTBACKGROUND: When compared with warfarin, low-molecular-weight heparin (LMWH) reduces the incidence of recurrent venous thromboembolism (VTE) in cancer. However, a survival benefit of LMWH over warfarin for the treatment of cancer-associated VTE has not been established.METHODS: Using the Surveillance, Epidemiology and End Results (SEER) and Medicare linked database from 2007 through 2016, we identified Medicare beneficiaries (aged ≥66 years) who were: (1) diagnosed with primary gastric, colorectal, pancreatic, lung, ovarian, or brain can...
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research
Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02015-6. Online ahead of print.ABSTRACTPancreatic cancer is associated with both family and hereditary cancer syndromes. Multigene panel testing for pancreatic cancer detected the germline variants BRCA1/2, PALB2, ATM, TP53, MLH1, STK11/LKB1, APC, CDKN2A, and SPINK1/PRSS1 as high-risk genes. A latest genome-wide association study revealed the common, but low-risk germline variants in pancreatic cancer patients. Active pancreatic surveillance using magnetic resonance imaging and endoscopic ultrasound is recommended for high-risk individuals who have a family history of p...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer